Side-by-side comparison of AI visibility scores, market position, and capabilities
AI healthcare communication platform handling patient scheduling, billing, and prescriptions; backed by Accel and YC quadrupling revenue while serving a $5B health insurance provider.
Clarion is an AI healthcare communication platform that deploys intelligent voice and messaging agents to handle high-volume patient interactions for clinics and health systems — automating appointment scheduling, billing inquiries, prescription refill requests, and patient follow-up communications that currently consume significant front-office staff time. Founded in 2024 and backed by Accel, Y Combinator, and Sequoia Scout with $5.4-5.8 million raised, Clarion has quadrupled revenue in recent months while serving tens of thousands of patients monthly across virtual care companies, health systems, and a $5 billion health insurance provider.\n\nClarion's AI agents handle patient-initiated contacts across phone, SMS, and web channels — scheduling appointments without hold times, answering billing questions, processing routine prescription refill requests, and sending proactive outreach for appointment reminders and care gap closures. The agents integrate with EHR systems (Epic, athenahealth) and practice management systems to access patient records and schedule availability, enabling context-aware conversations that feel more like interacting with an informed staff member than a phone tree.\n\nIn 2025, Clarion competes in the healthcare AI communication and patient engagement market with Nuance (Microsoft Dragon Ambient and DAX), Relatient (patient scheduling and communication), and Klara (patient messaging platform) for healthcare front-office automation. The healthcare front office represents one of the most labor-intensive and patient-satisfaction-critical functions in a medical practice — phone hold times and scheduling difficulties are top complaints from patients. Accel and Sequoia Scout backing at the seed stage reflects conviction about the market size and Clarion's early commercial traction. The 2025 strategy focuses on growing within health systems and virtual care companies, deepening EHR integrations, and expanding the AI agent capabilities to handle more complex patient interaction types beyond routine scheduling.
Precision birth control test using hormone and genetic data to personalize contraceptive selection; $2.65M from Lux Capital and M13 addressing trial-and-error that leaves millions on wrong contraceptives.
adyn is a precision medicine company developing personalized birth control solutions through at-home testing kits that analyze hormone levels and genetic risk factors — enabling individuals to choose hormonal contraceptives based on their own biology rather than trial-and-error, addressing a gap where most people cycle through multiple birth control options over years to find what works without causing intolerable side effects. Founded in 2019 and a Y Combinator graduate, adyn raised $2.65 million in seed funding co-led by Lux Capital and M13, with the Birth Control Optimization Test positioned as the first biology-based test for contraceptive personalization.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.